Actavis Glipizide 2.5mg Tablets Recall: Failed Dissolution Testing
Actavis recalls Glipizide extended-release tablets (2.5mg, 30-count) due to failed dissolution testing. Affected lots expire through June 2017. No action needed for safe use.
Lower-risk recall
Failed Dissolution Specifications. Above out of specification for dissolution rate observed at the 10 hour testing point.
Contact the company
What happened, in plain English
Actavis is recalling Glipizide extended-release tablets (2.5mg, 30-count) because they failed dissolution testing. This means the medication may not work properly when taken as directed, potentially leading to ineffective blood sugar control. Read more at govinfonow.com/recall/42062-actavis-glipizide-2-5mg-tablets-recall-failed-dissolution-testing.
Source Summary by GovInfoNow · govinfonow.com/recall/42062-actavis-glipizide-2-5mg-tablets-recall-failed-dissolution-testing · Updated October 8, 2026 · FDA enforcement record: FDA #D-0476-2017
Cite this page
“Actavis Glipizide 2.5mg Tablets Recall: Failed Dissolution Testing.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/42062-actavis-glipizide-2-5mg-tablets-recall-failed-dissolution-testing. Based on FDA recall #D-0476-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0476-2017%22&limit=1).
Why it’s dangerous
The tablets failed dissolution testing, meaning they may not release the medication properly in the body. This could lead to ineffective blood sugar control if the medication doesn't work as intended.
Who’s affected
People with prescriptions for Glipizide extended-release tablets (2.5mg, 30-count) from Actavis. Those with diabetes who take this medication are most at risk.
How to tell if you have this one
Check for the product name 'Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only'. Look for lot numbers 3134201, 3134202, 3134319, 3135246, 3135247, 3136781, 3136782, 3136903, 3136904, 3138250, 3138968, or 3140000. The expiration dates range from May 31, 2017 to September 30, 2017.
- Brand
Actavis- Product
Glipizide extended-release tablets, 2.5mg, 30-count bottle, Rx Only, Manufactured By Patheon Pharmaceuticals Inc- Category
Drug
What to do — step by step
Check Product Details
Verify the product name and lot numbers to confirm if your tablets are affected.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in US” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 13 months after the firm started it.
- Firm started the recall
- FDA classified it Class II
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Questions people ask
Do I need to stop using these tablets?
No action is needed for safe use. The recall is for testing purposes, not a safety hazard.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0476-2017 (January 30, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0476-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.